# Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

> **NCT01143064** · PHASE3 · COMPLETED · sponsor: **BHR Pharma, LLC** · enrollment: 1195 (actual)

## Conditions studied

- Brain Injuries

## Interventions

- **DRUG:** Progesterone
- **DRUG:** Lipid emulsion without progesterone

## Key facts

- **NCT ID:** NCT01143064
- **Lead sponsor:** BHR Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 1195 (ACTUAL)
- **Last updated:** 2024-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01143064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01143064, "Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT01143064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*